Clinical Dilemmas in Inflammatory Bowel Disease
Herausgegeben von Irving, Peter; Siegel, Corey A.; Rampton, David; Shanahan, Fergus
Clinical Dilemmas in Inflammatory Bowel Disease
Herausgegeben von Irving, Peter; Siegel, Corey A.; Rampton, David; Shanahan, Fergus
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
The second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice.
In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical…mehr
- Inflammatory Bowel Disease and Irritable Bowel Syndrome135,99 €
- Inflammatory Bowel Disease: Clinical Gastroenterology140,99 €
- Handbook of Inflammatory Bowel Disease140,99 €
- Pediatric Inflammatory Bowel Disease, an Issue of Gastroenterology Clinics of North America81,99 €
- Tonya KaltenbachNonpolypoid Colorectal Neoplasms in Inflammatory Bowel Disease, an Issue of Gastrointestinal Endoscopy Clinics57,99 €
- Colitis and Crohn's: Understanding and Managing Inflammatory Bowel Disease140,99 €
- Bo ShenInterventional Inflammatory Bowel Disease: Endoscopic Treatment of Complications, an Issue of Gastrointestinal Endoscopy Clinics78,99 €
-
-
-
In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking.
Each of the 57 evidence-based chapters contains clear learning points, addresses different topics, and provides sound guidance on subjects ranging from optimizing current management through to special management problems and novel treatments.
This book is suitable for all medical professionals involved in the care of patients with IBD: established and trainee gastroenterologists, colorectal surgeons, pathologists, radiologists, specialist nurses, pharmacists, dieticians and counselors.
- Produktdetails
- Verlag: Wiley & Sons / Wiley-Blackwell
- 2. Aufl.
- Seitenzahl: 288
- Erscheinungstermin: 12. Dezember 2011
- Englisch
- Abmessung: 242mm x 184mm x 20mm
- Gewicht: 680g
- ISBN-13: 9781444334548
- ISBN-10: 1444334549
- Artikelnr.: 33684558
- Verlag: Wiley & Sons / Wiley-Blackwell
- 2. Aufl.
- Seitenzahl: 288
- Erscheinungstermin: 12. Dezember 2011
- Englisch
- Abmessung: 242mm x 184mm x 20mm
- Gewicht: 680g
- ISBN-13: 9781444334548
- ISBN-10: 1444334549
- Artikelnr.: 33684558
will take us further in IBD - study of coding variation or epigenetics?
(Miles Parkes). 2 IBD in different ethnic groups: same or different?
(Rupert W.L. Leong, Dorothy K.L. Chow and Christian P. Selinger). Part 2:
Bugs and IBD - good, bad or indifferent? 3 How does the risk of infection
influence management of IBD around the world? (Kiran K. Peddi and Ian Craig
Lawrance). 4 Travelling with IBD (Ing Shian Soon and Gilaad Kaplan). 5 What
to do about hepatitis B and hepatitis C in patients with IBD (Morven
Cunningham and Graham R. Foster). 6 CMV in IBD - passenger or pathogen?
(Ahmed Kandiel & Bret Lashner). 7 Clostridium difficile in IBD: Impact,
Prevention and Treatment (Ashwin N. Ananthakrishnan and David G. Binion). 8
Pre- and synbiotics: placebo or panacea (James O. Lindsay). 9 Worms - light
at the end of their burrow? (John Leung and Joel V. Weinstock). 10 Do we
really need to vaccinate all patients with IBD? (Gauree Gupta and Gil Y.
Melmed). Part 3: Investigating IBD. 11 Biomarkers in IBD: myth or marvel?
(Richard B. Gearry, Andrew S. Day). 12 Radiation exposure in IBD: how do we
minimize the dangers? (Owen J O'Connor, Alan N. Desmond, Fergus Shanahan
and Michael M. Maher). 13 Surveillance colonoscopy in UC - what's the best
way to do it? (Matt Rutter). Part 4: Medical therapy. 5-ASA. 14 New 5ASAs:
a tiny step or giant stride forward? (L. Campbell Levy). 15 Do 5ASAs
prevent cancer? (Richard Logan and Venkataraman Subramanian). 16 Why do we
still use 5-ASAs in Crohns disease? (Stephen Hanauer, Henit Yanai, Emma
Calabrese). Steroids. 17 Steroids in Crohn's disease: do the benefits
outweigh the dangers? (A. Hillary Steinhart). Immunomodulators. 18
Thioguanine nucleotide measurement: Non-adherent, shunter, under-dosed or
resistant? (Miles Sparrow). 19 Thiopurines and the sun: what should be
done? (Conal M. Perrett, Jane M. McGregor, Catherine A. Harwood). 20 Do
thiopurines worsen risk and prognosis of cervical neoplasia? (Jeremy D.
Sanderson and Melissa A. Smith). 21 Optimising use of methotrexate (Anna
Foley and Peter R. Gibson). 22 Which calcineurin inhibitor and when? (A.
Barney Hawthorne). Biologics. 23 Are all anti-TNF agents the same?
(Jennifer L. Jones). 24 One drug or two: Do patients on biologics need
concurrent immunomodulation? (Glen A. Doherty and Adam S. Cheifetz). 25 How
do we identify patients needing early aggressive therapy and what should we
use? (Marc Ferrante and Séverine Vermeire). 26 What is the role of
biologics in UC? (Joanna K. Law and Brian Bressler). 27 What can we do with
Crohn's patients refractory to antiTNF therapy? (David T. Rubin). 28 Which
EIMs respond to biologics? (Tina A. Mehta and CS Probert). 29 Use and abuse
of biologics in pregnancy (Marla C. Dubinsky). 30 Is anti-TNF therapy safe
to use in people with a history of malignancy? (Mark Lust and Simon
Travis). 31 What and how should we tell patients about the risks of
immunomodulators and biologics? (Corey A Siegel). 32 When, how and in whom
should we stop biologics? (Edouard Louis, Jacques Belaiche, Catherine
Reenaers). Part 5: Other treatments. 33 Avoiding drug interactions (Tim
Elliott and Peter M. Irving). 34 Is there still a role for ursodeoxycholic
acid treatment in patients with inflammatory bowel disease associated with
primary sclerosing cholangitis? (Emmanouil Sinakos & Keith Lindor). 35 Stem
cell transplantation for Crohn's: what's the risk-benefit ratio?
(Venkataraman Subramanian and Christopher J Hawkey). 36 Complementary
Therapy: Is There a Needle in the Haystack? (Shane M. Devlin). Part 6:
Surgical Dilemmas in IBD. 37 Optimising IBD patients for surgery and
recovery (Jonathan Wilson and Alastair Windsor). 38 Is surgery the best
initial treatment for limited ileocaecal Crohn's disease? (Tom Øresland).
39 Laparoscopic or open surgery for IBD? (Donna Appleton and Michael
Hershman). 40 Perianal Crohn's disease - optimal management (David A.
Schwartz and Norman R. Clark III). 41 Does anti-TNF therapy increase the
risk of Complications of surgery? (Ming Valerie Lin, Wojciech Blonski and
Gary R. Lichtenstein). 42 Pouches for Indeterminate Colitis and Crohn's
Disease: Act Now, Pay Later? (Phillip Fleshner). 43 Dealing with pouchitis
(Bo Shen and Simon McLaughlin). Part 7: Unsolved issues in IBD. 44 Mucosal
healing in IBD - does it matter? (Geert D'Haens). 45 Vitamin D in IBD: from
genetics to bone health via cancer and immunology (Helen M. Pappa and
Richard J. Grand). 46 Got Milk? Medication Use and Nursing in Women with
IBD (Sunanda Kane). 47 Does stress matter? (Robert Maunder). 48 IBS is
common in IBD: fact or fallacy? (James Goodhand & David Rampton). 49 So
where is all the cancer? (Judith E. Baars & C. Janneke van der Woude). Part
8: Nutrition in IBD. 50 What should patients with IBD eat? (Emile Richman,
Keith Leiper, Jonathan Rhodes). 51 Enteral Nutrition in Crohn's - Who for,
When, How and Which Formula? (R. Shamir and Ernest G. Seidman). 52
Optimizing treatment of iron deficiency anemia (Hermann Schulze and Axel
Dignass). Part 9: Management process. 53 IBD Standards: will they enhance
patient care? (Michael D. Kappelman). 54 Your treatment won't work if the
patient doesn't take it (Rob Horne). 55 Inflammatory Bowel Disease: What to
tell your ED team (Louise Langmead). 56 Transitioning from pediatric to
adult care (Elizabeth J. Hait and Laurie N. Fishman). 57 Medicolegal
Pitfalls in Inflammatory Bowel Disease (IBD) Care (William J. Tremaine).
will take us further in IBD - study of coding variation or epigenetics?
(Miles Parkes). 2 IBD in different ethnic groups: same or different?
(Rupert W.L. Leong, Dorothy K.L. Chow and Christian P. Selinger). Part 2:
Bugs and IBD - good, bad or indifferent? 3 How does the risk of infection
influence management of IBD around the world? (Kiran K. Peddi and Ian Craig
Lawrance). 4 Travelling with IBD (Ing Shian Soon and Gilaad Kaplan). 5 What
to do about hepatitis B and hepatitis C in patients with IBD (Morven
Cunningham and Graham R. Foster). 6 CMV in IBD - passenger or pathogen?
(Ahmed Kandiel & Bret Lashner). 7 Clostridium difficile in IBD: Impact,
Prevention and Treatment (Ashwin N. Ananthakrishnan and David G. Binion). 8
Pre- and synbiotics: placebo or panacea (James O. Lindsay). 9 Worms - light
at the end of their burrow? (John Leung and Joel V. Weinstock). 10 Do we
really need to vaccinate all patients with IBD? (Gauree Gupta and Gil Y.
Melmed). Part 3: Investigating IBD. 11 Biomarkers in IBD: myth or marvel?
(Richard B. Gearry, Andrew S. Day). 12 Radiation exposure in IBD: how do we
minimize the dangers? (Owen J O'Connor, Alan N. Desmond, Fergus Shanahan
and Michael M. Maher). 13 Surveillance colonoscopy in UC - what's the best
way to do it? (Matt Rutter). Part 4: Medical therapy. 5-ASA. 14 New 5ASAs:
a tiny step or giant stride forward? (L. Campbell Levy). 15 Do 5ASAs
prevent cancer? (Richard Logan and Venkataraman Subramanian). 16 Why do we
still use 5-ASAs in Crohns disease? (Stephen Hanauer, Henit Yanai, Emma
Calabrese). Steroids. 17 Steroids in Crohn's disease: do the benefits
outweigh the dangers? (A. Hillary Steinhart). Immunomodulators. 18
Thioguanine nucleotide measurement: Non-adherent, shunter, under-dosed or
resistant? (Miles Sparrow). 19 Thiopurines and the sun: what should be
done? (Conal M. Perrett, Jane M. McGregor, Catherine A. Harwood). 20 Do
thiopurines worsen risk and prognosis of cervical neoplasia? (Jeremy D.
Sanderson and Melissa A. Smith). 21 Optimising use of methotrexate (Anna
Foley and Peter R. Gibson). 22 Which calcineurin inhibitor and when? (A.
Barney Hawthorne). Biologics. 23 Are all anti-TNF agents the same?
(Jennifer L. Jones). 24 One drug or two: Do patients on biologics need
concurrent immunomodulation? (Glen A. Doherty and Adam S. Cheifetz). 25 How
do we identify patients needing early aggressive therapy and what should we
use? (Marc Ferrante and Séverine Vermeire). 26 What is the role of
biologics in UC? (Joanna K. Law and Brian Bressler). 27 What can we do with
Crohn's patients refractory to antiTNF therapy? (David T. Rubin). 28 Which
EIMs respond to biologics? (Tina A. Mehta and CS Probert). 29 Use and abuse
of biologics in pregnancy (Marla C. Dubinsky). 30 Is anti-TNF therapy safe
to use in people with a history of malignancy? (Mark Lust and Simon
Travis). 31 What and how should we tell patients about the risks of
immunomodulators and biologics? (Corey A Siegel). 32 When, how and in whom
should we stop biologics? (Edouard Louis, Jacques Belaiche, Catherine
Reenaers). Part 5: Other treatments. 33 Avoiding drug interactions (Tim
Elliott and Peter M. Irving). 34 Is there still a role for ursodeoxycholic
acid treatment in patients with inflammatory bowel disease associated with
primary sclerosing cholangitis? (Emmanouil Sinakos & Keith Lindor). 35 Stem
cell transplantation for Crohn's: what's the risk-benefit ratio?
(Venkataraman Subramanian and Christopher J Hawkey). 36 Complementary
Therapy: Is There a Needle in the Haystack? (Shane M. Devlin). Part 6:
Surgical Dilemmas in IBD. 37 Optimising IBD patients for surgery and
recovery (Jonathan Wilson and Alastair Windsor). 38 Is surgery the best
initial treatment for limited ileocaecal Crohn's disease? (Tom Øresland).
39 Laparoscopic or open surgery for IBD? (Donna Appleton and Michael
Hershman). 40 Perianal Crohn's disease - optimal management (David A.
Schwartz and Norman R. Clark III). 41 Does anti-TNF therapy increase the
risk of Complications of surgery? (Ming Valerie Lin, Wojciech Blonski and
Gary R. Lichtenstein). 42 Pouches for Indeterminate Colitis and Crohn's
Disease: Act Now, Pay Later? (Phillip Fleshner). 43 Dealing with pouchitis
(Bo Shen and Simon McLaughlin). Part 7: Unsolved issues in IBD. 44 Mucosal
healing in IBD - does it matter? (Geert D'Haens). 45 Vitamin D in IBD: from
genetics to bone health via cancer and immunology (Helen M. Pappa and
Richard J. Grand). 46 Got Milk? Medication Use and Nursing in Women with
IBD (Sunanda Kane). 47 Does stress matter? (Robert Maunder). 48 IBS is
common in IBD: fact or fallacy? (James Goodhand & David Rampton). 49 So
where is all the cancer? (Judith E. Baars & C. Janneke van der Woude). Part
8: Nutrition in IBD. 50 What should patients with IBD eat? (Emile Richman,
Keith Leiper, Jonathan Rhodes). 51 Enteral Nutrition in Crohn's - Who for,
When, How and Which Formula? (R. Shamir and Ernest G. Seidman). 52
Optimizing treatment of iron deficiency anemia (Hermann Schulze and Axel
Dignass). Part 9: Management process. 53 IBD Standards: will they enhance
patient care? (Michael D. Kappelman). 54 Your treatment won't work if the
patient doesn't take it (Rob Horne). 55 Inflammatory Bowel Disease: What to
tell your ED team (Louise Langmead). 56 Transitioning from pediatric to
adult care (Elizabeth J. Hait and Laurie N. Fishman). 57 Medicolegal
Pitfalls in Inflammatory Bowel Disease (IBD) Care (William J. Tremaine).